Xenon Pharmaceuticals CCO Christopher Von Seggern departs; consulting agreement through May 2025

Xenon Pharmaceuticals Inc.

Christopher Von Seggern ceased as Chief Commercial Officer on January 17, 2025.
Separation Agreement provides severance per 2020 offer letter and 2024 annual bonus.
Consulting Agreement through May 1, 2025; equity awards continue vesting until then.
No replacement named for the CCO role.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Von Seggern

Chief Commercial Officer

XENE · Xenon Pharmaceuticals Inc.

Effective: 2025-01-17
Filed: January 17, 2025, 6:59 PM ET

On January 17, 2025, Christopher Von Seggern ceased to be the Chief Commercial Officer of Xenon Pharmaceuticals Inc. (the “Company”) and departed the Company as of such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Von Seggern departed as Chief Commercial Officer at Xenon Pharmaceuticals Inc..

Action: ceased
Role: Chief Commercial Officer

Exact text from the filing

On January 17, 2025, Christopher Von Seggern ceased to be the Chief Commercial Officer of Xenon Pharmaceuticals Inc. (the “Company”) and departed the Company as of such date.

View on SEC.gov

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-006495

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.